ArticleBMC immunology2025

Enfortumab vedotin promotes PD-L1 expression in urothelial carcinoma via NF-κB and STAT3 pathways highlighting mechanisms of immune evasion and potential for combination therapy.

Hirohito Naito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.